ClinicalTrials.gg
CompletedNCT05083923Updated Oct 24, 2025Results posted

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

A Phase 3 interventional study of Diroximel fumarate in Relapsing Forms of Multiple Sclerosis, sponsored by Biogen. Completed at 52 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-24.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Multiple Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Sclerosis · Biogen.

Enrollment
35th of 79
136 · median 110
Started
2021
with 8 others
Phase 3
28 of 127
1 open now
Registered
116th of 127
by date

Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 35th largest by enrollment of the 79 interventional ones that give a count, is one of 9 that started in 2021, is one of 28 in phase 3, and was the 116th registered.

Multiple Sclerosis

3,269 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 127 studies in Multiple Sclerosis by Biogen are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Multiple Sclerosis by Biogen, or all of them as a file.
02

Study summary

The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF administered for up to 48 weeks in adult East Asian participants with RMS (Part 2).

The secondary objective of this study is to evaluate the pharmacokinetic(s) (PK) of DRF metabolites (monomethyl fumarate [MMF] and 2-hydroxyethyl succinimide [HES]) following multiple doses of DRF in a subset of adult East Asian participants with RMS (Part 1).

03

Conditions studied

  • Relapsing Forms of Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a diagnosis of RMS, as defined by revised 2017 McDonald's criteria.
  • Expanded Disability Status Scale (EDSS) score between 0.0 and 5.0, inclusive, at screening and baseline visit (Day 1).
  • Neurologically stable with no evidence of relapse within 30 days prior to baseline visit (Day 1).
  • For Japanese participants: Born in Japan and biological parents and grandparents were of Japanese origin. If previously lived outside of Japan for more than 5 years, must not have had a significantly modified diet since leaving Japan.
  • For Chinese participants: Born in China, and biological parents and grandparents were of Chinese origin. If previously lived outside of China for more than 5 years, must not have had a significantly modified diet since leaving China.

Key Exclusion Criteria:

  • Has a multiple sclerosis (MS) relapse that has occurred within the 30 days prior to randomization and/or the participant has not stabilized from a previous relapse prior to randomization.
  • History of severe allergic or anaphylactic reactions or of any allergic reactions that, in the opinion of the investigator, are likely to be exacerbated by any component of the study treatment.
  • History of, or ongoing, malignant disease, including solid tumors and hematologic .
  • Has a history of gastrointestinal (GI) surgery (except appendectomy or cholecystectomy that occurred more than 6 months prior to screening), irritable bowel syndrome, inflammatory bowel disease (Crohn's disease, ulcerative colitis), or other and active GI condition per the investigator's discretion.
  • History of clinically significant recurring or active GI symptoms (e.g., nausea, diarrhea, dyspepsia, constipation) within 90 days of screening, including symptoms that require the initiation of symptomatic medical treatment (e.g., initiation of a medication to treat gastroesophageal reflux disease) or a change in symptomatic medical treatment (e.g., an increase in dose) within 90 days prior to screening.
  • History of systemic reaction to DRF, dimethyl fumarate (DMF), MMF or other fumaric esters, the contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.
  • Evidence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 14 days prior to Screening, between screening and baseline visit (Day 1), or at baseline visit (Day 1), including but not limited to a fever (temperature >37.5 degrees Celsius [°C]), new and persistent cough, breathlessness, or loss of taste and/or smell. Evidence of current SARS-CoV-2 infection within 14 days prior to Screening or during Screening, will be eligible for rescreening, provided that the participant is asymptomatic for 14 days prior to rescreening.
  • Have close contact within 14 days prior to Day 1 with individual(s) with suspected SARS-CoV-2 infection.
  • For participants who had close contact with individual(s) with suspected SARS-CoV-2 infection within 14 days prior to Day 1, as determined by the Investigator, will be eligible for rescreening, provided that the participant is asymptomatic for 14 days after the contact.
  • History or positive test result at screening for (HIV).
  • Previous participation in this study or previous studies with DRF, DMF, or MMF.
  • Has a clinically significant history of suicidal ideation or suicidal behavior occurring in the past 12 months as assessed by the C-SSRS at Screening.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Diroximel Fumarate (DRF)

    Japanese and Chinese participants will initiate treatment with DRF 231 milligrams (mg), oral capsule, twice daily on Day 1 through Day 7, followed by DRF 462 mg, oral capsules, twice daily from Day 8 up to Week 48.

    Drug: Diroximel fumarate

Interventions

  • Administered as specified in the treatment arm

    Also known as: Vumerity, BIIB098, ALK8700

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether/not related to the medicinal (investigational) product. An AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment, or completion of the safety follow-up visit, if applicable.(i.e. for participants who prematurely discontinued study treatment or withdrew from the study) . An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs.

    Time frame: Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)

  2. Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

    Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.

    Time frame: Baseline (Day 1) to Week 24

  3. Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values

    The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.

    Time frame: Baseline (Day 1) to Week 24

  4. Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters

    Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees Celsius (C), pulse rate \< 60 and \> 100 beats per minute (bpm), systolic blood pressure (\< 90, \> 140 and \> 160 millimeters of mercury \[mmHg\]), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.

    Time frame: Baseline (Day 1) to Week 24

  5. Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

    Time frame: Baseline (Day 1) to Week 24

  6. Parts 1 and 2: Number of Participants With TEAEs and TESAEs

    An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal (investigational) product, whether/not related to medicinal (investigational) product. AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment. SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs. TEAEs and TESAEs for participants were collected cumulatively for Parts 1 and 2.

    Time frame: From Day 1 up to the end of the study (up to Week 50)

  7. Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

    Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.

    Time frame: Baseline (Day 1) to Week 48

  8. Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values

    The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.

    Time frame: Baseline (Day 1) to Week 48

  9. Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters

    Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees C, pulse rate \< 60 and \> 100 bpm, systolic blood pressure (\< 90, \> 140 and \> 160 mmHg), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.

    Time frame: Baseline (Day 1) to Week 48

  10. Part 2: Number of Participants With C-SSRS Events

    The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

    Time frame: Baseline (Day 1) to Week 48

Secondary outcomes

  1. Part 1: Plasma Concentrations of Monomethyl Fumarate (MMF)-Intensive Pharmacokinetic (PK) Analysis Set

    Summarized data for plasma concentration of MMF at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  2. Part 1: Plasma Concentration of 2-Hydroxyethyl Succinimide (HES)-Intensive PK Analysis Set

    Summarized data for plasma concentration of HES at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  3. Part 1: Plasma Concentrations of MMF-Sparse PK Analysis Set

    Time frame: Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57

  4. Part 1: Plasma Concentrations of HES-Sparse PK Analysis Set

    Time frame: Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57

  5. Part 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set

    Summarized data for Cmax at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  6. Part 1: Cmax of HES-Intensive PK Analysis Set

    Summarized data for Cmax at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  7. Part 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set

    Summarized data for AUClast at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  8. Part 1: AUClast of HES-Intensive PK Analysis Set

    Summarized data for AUClast at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  9. Part 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set

    Summarized data for Tmax at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  10. Part 1: Tmax of HES-Intensive PK Analysis Set

    Summarized data for Tmax at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

  11. Part 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set

    Summarized data for t½ at all timepoints is reported.

    Time frame: Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169

07

Results

Posted Oct 24, 2025

Participant flow

Participants took part in the multiple investigative sites from 18 November 2021 to 11 September 2024.

Participant flow — Overall Study
MilestoneCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Started5250
Completed4740
Not completed510
Withdrew: Adverse event20
Withdrew: Lack of efficacy13
Withdrew: Withdrawal by subject26
Withdrew: Reason not specified01

Outcome measures

PrimaryPart 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether/not related to the medicinal (investigational) product. An AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment, or completion of the safety follow-up visit, if applicable.(i.e. for participants who prematurely discontinued study treatment or withdrew from the study) . An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs.

Time frame:
Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
TEAEs5045
TESAEs35
PrimaryPart 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Leukocytes <=2.8 x 10^9 per liter (L)31
Lymphocytes <0.91 x 10^9/L2511
Lymphocytes <0.8 x 10^9/L153
Lymphocytes <0.5 x 10^9/L20
Neutrophils <1.5 x 10^9/L52
Neutrophils<1 x 10^9/L10
Eosinophils >1.0 x 10^9/L70
Hemoglobin <=95 gram per liter (g/L) for Female or <=115g/L for Male01
Platelets <=75 x 10^9/L00
Platelets >=700 x 10^9/L00
Alanine Aminotransferase >=3 x upper limit of normal (ULN)73
Alanine Aminotransferase >5 x ULN10
Alanine Aminotransferase >10 x ULN00
Aspartate Aminotransferase >=3 x ULN20
Aspartate Aminotransferase >5 x ULN00
Aspartate Aminotransferase >10 x ULN00
Alkaline Phosphatase >3 x ULN00
Alkaline Phosphatase >5 x ULN00
Alkaline Phosphatase >10 x ULN00
Gamma Glutamyl Transferase >=3 x ULN31
Bilirubin >1.5 x ULN01
Bilirubin >2 x ULN00
Urea Nitrogen >10.71 Millimoles per Liter (mmol/L)00
Creatinine >=176.8 Micromole per Litre (umol/L)00
Bicarbonate <15 mmol/L00
Bicarbonate >31 mmol/L00
Ketones >=4+10
Protein >=2+10
PrimaryPart 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values

The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values53
PrimaryPart 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters

Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees Celsius (C), pulse rate \< 60 and \> 100 beats per minute (bpm), systolic blood pressure (\< 90, \> 140 and \> 160 millimeters of mercury \[mmHg\]), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Temperature <36 degrees C82
Temperature >38 degrees C10
Pulse Rate <60 bpm93
Pulse Rate >100 bpm42
Systolic Blood Pressure <90 mmHg41
Systolic Blood Pressure >140 mmHg21
Systolic Blood Pressure >160 mmHg01
Diastolic Blood Pressure <50 mmHg20
Diastolic Blood Pressure >90 mmHg134
Diastolic Blood Pressure >100 mmHg20
Weight 7% or more increase from baseline15
Weight 7% or more decrease from baseline32
Respiratory Rate <12 breaths/min30
Respiratory Rate >20 breaths/min80
PrimaryPart 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

Time frame:
Baseline (Day 1) to Week 24
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Suicidal Ideation01
Suicidal Behavior00
Non-suicidal Self-injurious Behavior00
PrimaryParts 1 and 2: Number of Participants With TEAEs and TESAEs

An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with use of medicinal (investigational) product, whether/not related to medicinal (investigational) product. AE was considered treatment-emergent if it starts or worsens on or after the date of the first dose of study drug in the study until 1 day after the last dose of treatment. SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, is a medically important event. TEAEs included both serious and non-serious TEAEs. TEAEs and TESAEs for participants were collected cumulatively for Parts 1 and 2.

Time frame:
From Day 1 up to the end of the study (up to Week 50)
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With TEAEs and TESAEs
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
TEAEs5247
TESAEs66
PrimaryPart 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters

Laboratory assessments included hematology, blood chemistry, and urinalysis parameters. Hematology parameters:basophils, hematocrit, red blood cell, total and differential leukocytes, platelets, lymphocytes, monocytes, neutrophils, eosinophils, hemoglobin. Blood chemistry parameters:sodium, potassium, chloride, glucose, calcium, uric acid, total protein, albumin, creatine phosphokinase, Lipid profile: blood cholesterol,high-density lipoprotein,low-density lipoprotein, and triglycerides,serum follicle-stimulating hormone,Vitamin D,thyroid stimulating hormone,serum pregnancy, HIV/Hepatitis screen,tuberculosis test,alanine aminotransferase,aspartate aminotransferase,Lactate Dehydrogenase,alkaline phosphatase,gamma glutamyl transferase,total bilirubin,blood urea nitrogen,creatinine and bicarbonate. Urinalysis parameters:color,pH,specific gravity,ketones,protein,glucose, bilirubin,nitrite,urobilinogen,occult blood,microscopic examination,urine albumin,beta-2-microglobulin,urine creatinine.

Time frame:
Baseline (Day 1) to Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Leukocytes <=2.8 x 10^9/L63
Lymphocytes <0.91 x 10^9/L2816
Lymphocytes <0.8 x 10^9/L2011
Lymphocytes <0.5 x 10^9/L51
Neutrophils <1.5 x 10^9/L84
Neutrophils <1 x 10^9/L22
Eosinophils >1.0 x 10^9/L70
Hemoglobin <=95g/L for Female or <=115g/L for Male32
Platelets <=75 x 10^9/L00
Platelets >=700 x 10^9/L00
Alanine Aminotransferase >=3 x ULN74
Alanine Aminotransferase >5 x ULN10
Alanine Aminotransferase >10 x ULN00
Aspartate Aminotransferase >=3 x ULN20
Aspartate Aminotransferase >5 x ULN00
Aspartate Aminotransferase >10 x ULN00
Alkaline Phosphatase >3 x ULN00
Alkaline Phosphatase >5 x ULN00
Alkaline Phosphatase >10 x ULN00
Gamma Glutamyl Transferase >=3 x ULN42
Bilirubin >1.5 x ULN01
Bilirubin >2 x ULN00
Urea Nitrogen >10.71 mmol/L00
Creatinine >=176.8 umol/L00
Bicarbonate <15 mmol/L00
Bicarbonate >31 mmol/L00
Ketones >=4+10
Protein >=2+30
PrimaryPart 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values

The number of participants with shifts to categorical values of ECG interpretation (e.g. abnormal) were presented by each cohort. Abnormal shift includes a shift from normal or unknown to abnormal.

Time frame:
Baseline (Day 1) to Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values75
PrimaryPart 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters

Vital sign assessment included temperature, pulse rate systolic blood pressure, diastolic blood pressure, and respiratory rate. The criteria for determining potentially clinically relevant abnormalities in vital signs included: temperature \< 36 and \> 38 degrees C, pulse rate \< 60 and \> 100 bpm, systolic blood pressure (\< 90, \> 140 and \> 160 mmHg), diastolic blood pressure \< 50, \> 90 and \> 100 mmHg, weight (7% or more increase from baseline, 7% or more decrease from baseline) and respiratory rate \< 12 and \> 20 breaths per minute.

Time frame:
Baseline (Day 1) to Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Temperature <36 degrees C122
Temperature >38 degrees C10
Pulse Rate <60 bpm97
Pulse Rate >100 bpm63
Systolic Blood Pressure <90 mmHg72
Systolic Blood Pressure >140 mmHg31
Systolic Blood Pressure >160 mmHg01
Diastolic Blood Pressure <50 mmHg31
Diastolic Blood Pressure >90 mmHg145
Diastolic Blood Pressure >100 mmHg40
Weight 7% or more increase from baseline36
Weight 7% or more decrease from baseline57
Respiratory Rate <12 breaths/min60
Respiratory Rate >20 breaths/min131
PrimaryPart 2: Number of Participants With C-SSRS Events

The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation, suicidal behavior and non-suicidal self-injurious behavior. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, Suicidal behavior, completed suicide), suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan and intent) and non-suicidal self-injurious behavior.

Time frame:
Baseline (Day 1) to Week 48
Reported as:
Count of participants · Participants
Part 2: Number of Participants With C-SSRS Events
ParticipantsCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Suicidal Ideation02
Suicidal Behavior00
Non-suicidal Self-injurious Behavior00
SecondaryPart 1: Plasma Concentrations of Monomethyl Fumarate (MMF)-Intensive Pharmacokinetic (PK) Analysis Set

Summarized data for plasma concentration of MMF at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Part 1: Plasma Concentrations of Monomethyl Fumarate (MMF)-Intensive Pharmacokinetic (PK) Analysis Set
Microgram per milliliter (ug/mL)Cohort 1: Japanese Participants
Pre-dose0.1 ± 67.69
0.5 Hour Post-dose0.1 ± 37.55
1 Hour Post-dose0.1 ± 73.60
2 Hours Post-dose0.2 ± 184.48
3 Hours Post-dose0.5 ± 210.05
4 Hours Post-dose0.9 ± 63.43
6 Hours Post-dose0.4 ± 88.04
8 Hours Post-dose0.1 ± 58.32
SecondaryPart 1: Plasma Concentration of 2-Hydroxyethyl Succinimide (HES)-Intensive PK Analysis Set

Summarized data for plasma concentration of HES at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · ug/mL
Part 1: Plasma Concentration of 2-Hydroxyethyl Succinimide (HES)-Intensive PK Analysis Set
ug/mLCohort 1: Japanese Participants
Pre-dose9.0 ± 23.11
0.5 Hour Post-dose8.7 ± 23.59
1 Hour Post-dose8.4 ± 28.42
2 Hour Post-dose8.4 ± 30.88
3 Hour Post-dose9.5 ± 23.84
4 Hour Post-dose9.5 ± 31.92
6 Hour Post-dose9.9 ± 45.11
8 Hour Post-dose11.2 ± 26.05
SecondaryPart 1: Plasma Concentrations of MMF-Sparse PK Analysis Set
Time frame:
Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57
Reported as:
Geometric mean · ug/mL
Part 1: Plasma Concentrations of MMF-Sparse PK Analysis Set
ug/mLCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Day 29 (Pre-dose)0.1 ± 79.060.1 ± 144.66
Day 29 (2-3 Hours Post-dose)0.9 ± 246.460.8 ± 223.71
Day 57 (Pre-dose)0.1 ± 90.080.1 ± 91.21
Day 57 (2-3 Hours Post-dose)0.7 ± 234.801.1 ± 131.05
SecondaryPart 1: Plasma Concentrations of HES-Sparse PK Analysis Set
Time frame:
Pre-dose and 2 to 3 hours post-dose on Day 29 and Day 57
Reported as:
Geometric mean · ug/mL
Part 1: Plasma Concentrations of HES-Sparse PK Analysis Set
ug/mLCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Day 29 (Pre-dose)8.2 ± 28.138.0 ± 32.54
Day 29 (2-3 Hours Post-dose)9.1 ± 37.579.7 ± 38.05
Day 57 (Pre-dose)8.4 ± 40.458.3 ± 34.97
Day 57 (2-3 Hours Post-dose)9.5 ± 34.599.7 ± 31.27
SecondaryPart 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set

Summarized data for Cmax at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · ug/mL
Part 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set
ug/mLCohort 1: Japanese Participants
Part 1: Maximum Observed Concentration (Cmax) of MMF-Intensive PK Analysis Set1.2 ± 56.85
SecondaryPart 1: Cmax of HES-Intensive PK Analysis Set

Summarized data for Cmax at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · ug/mL
Part 1: Cmax of HES-Intensive PK Analysis Set
ug/mLCohort 1: Japanese Participants
Part 1: Cmax of HES-Intensive PK Analysis Set11.6 ± 26.49
SecondaryPart 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set

Summarized data for AUClast at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · hour*microgram per milliliter (h*ug/mL)
Part 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set
hour*microgram per milliliter (h*ug/mL)Cohort 1: Japanese Participants
Part 1: Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration (AUClast) of MMF-Intensive PK Analysis Set3.6 ± 36.34
SecondaryPart 1: AUClast of HES-Intensive PK Analysis Set

Summarized data for AUClast at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Geometric mean · h*ug/mL
Part 1: AUClast of HES-Intensive PK Analysis Set
h*ug/mLCohort 1: Japanese Participants
Part 1: AUClast of HES-Intensive PK Analysis Set75.3 ± 29.31
SecondaryPart 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set

Summarized data for Tmax at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Median · hours
Part 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set
hoursCohort 1: Japanese Participants
Part 1: Time to Reach Cmax (Tmax) of MMF-Intensive PK Analysis Set3.8 (2 to 6)
SecondaryPart 1: Tmax of HES-Intensive PK Analysis Set

Summarized data for Tmax at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Median · hours
Part 1: Tmax of HES-Intensive PK Analysis Set
hoursCohort 1: Japanese Participants
Part 1: Tmax of HES-Intensive PK Analysis Set5.80 (0.5 to 7.9)
SecondaryPart 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set

Summarized data for t½ at all timepoints is reported.

Time frame:
Pre-dose and at 0.5,1,2,3,4,6, and 8 hours post-dose from Day 29 to Day 169
Reported as:
Median · hours
Part 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set
hoursCohort 1: Japanese Participants
Part 1: Elimination Half-Life (t½) of MMF-Intensive PK Analysis Set1.3 (0.8 to 1.3)

Adverse events

Collected over From Day 1 up to the end of the study (up to Week 50). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Japanese Participants0/52 (0%)6/52 (11.5%)50/52 (96.2%)
Cohort 2: Chinese Participants0/50 (0%)6/50 (12%)42/50 (84%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
Multiple sclerosis relapseNervous system disorders3/523/50
Iron deficiency anaemiaBlood and lymphatic system disorders0/521/50
DemyelinationNervous system disorders0/521/50
Relapsing-remitting multiple sclerosisNervous system disorders0/521/50
Staphylococcal bacteraemiaInfections and infestations1/520/50
FallInjury, poisoning and procedural complications1/520/50
Humerus fractureInjury, poisoning and procedural complications1/520/50
Foot deformityMusculoskeletal and connective tissue disorders1/520/50
OsteoarthritisMusculoskeletal and connective tissue disorders1/520/50
Most frequent other events
Showing 10 of 48
Most frequent other events
EventCohort 1: Japanese ParticipantsCohort 2: Chinese Participants
DiarrhoeaGastrointestinal disorders19/524/50
Upper respiratory tract infectionInfections and infestations6/5218/50
FlushingVascular disorders17/529/50
NasopharyngitisInfections and infestations11/522/50
Covid-19Infections and infestations9/525/50
Lymphocyte count decreasedInvestigations3/528/50
PyrexiaGeneral disorders8/524/50
Multiple sclerosis relapseNervous system disorders8/524/50
PruritusSkin and subcutaneous tissue disorders3/527/50
Weight decreasedInvestigations0/526/50

Baseline characteristics

Safety analysis set included all participants who had received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Cohort 1: Japanese ParticipantsCohort 2: Chinese ParticipantsTotal
Mean40.1 ± 9.5635.6 ± 10.4937.9 ± 10.23
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Japanese ParticipantsCohort 2: Chinese ParticipantsTotal
Female404282
Male12820
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Japanese ParticipantsCohort 2: Chinese ParticipantsTotal
Hispanic or Latino000
Not Hispanic or Latino5250102
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Japanese ParticipantsCohort 2: Chinese ParticipantsTotal
American Indian or Alaska Native000
Asian5250102
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

52 sites
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
  • Beijing Hospital
    Beijing, Beijing Municipality 100006, China
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing Municipality 100050, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Lanzhou University Second Hospital
    Lanzhou, Gansu 730030, China
  • Dongguan People's Hospital
    Dongguan, Guangdong 523059, China
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
  • Guangzhou First People's Hospital
    Guangzhou, Guangdong 510180, China
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510260, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The Third Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510630, China
  • Tangshan Gongren Hospital
    Tangshan, Hebei 063003, China
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150040, China
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
  • Xiangya Hospital, Central South University
    Changsha, Hu'nan 410008, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Wuhan, Hubei 430030, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 10050, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215004, China
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shengjing Hospital of China Medical University
    Shengyang, Liaoning 110004, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia Hui 750004, China
  • Tangdu Hospital, Fourth Military Medical University
    Xi'an, Shan'xi 710038, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
    Shanghai, Shanghai Municipality 200001, China
  • Shanxi Provincial People's Hospital
    Taiyuan, Shanxi 30012, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • Tianjin Medical University Affiliated General Hospital
    Tianjin, Tianjin Municipality 300052, China
  • First Affiliated Hospital of Kunming Medical University
    Kunming, Yun'nan 650032, China
  • Chiba University Hospital
    Chiba, Chiba 260-8677, Japan
  • Tokyo Womens Medical University Yachiyo Medical Center
    Yachiyo, Chiba 276-8524, Japan
  • Ehime University Hospital
    Toon-shi, Ehime 791-0295, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka 814-0180, Japan
  • Hospital of the University of Occupational and Environmental Health
    Kitakyushu-shi, Fukuoka 807-8556, Japan
  • Southern Tohoku Medical Clinic
    Koriyama-shi, Fukushima 963-8563, Japan
  • NHO Asahikawa Medical Center
    Asahikawa-shi, Hokkaido 070-8644, Japan
  • Obihiro Kosei Hospital
    Obihiro, Hokkaido 080-0024, Japan
  • NHO Hokkaido Medical Center
    Sapporo, Hokkaido 063-0005, Japan
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki 305-8576, Japan
  • Iwate Medical University Uchimaru Medical Center
    Morioka, Iwate 020-8505, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Tohoku Medical and Pharmaceutical University Hospital
    Sendai, Miyagi 983-8512, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, Niigata 951-8520, Japan
  • Kansai Medical University Medical Center
    Moriguchi-shi, Osaka 570-8507, Japan
  • Saitama Medical Center
    Kawagoe-shi, Saitama 350-8550, Japan
  • Juntendo University Hospital
    Bunkyō City, Tokyo-To 113-8431, Japan
  • National Center of Neurology and Psychiatry
    Kodaira-shi, Tokyo-To 187-8551, Japan
  • Ebara Hospital
    Ōta-ku, Tokyo-To 145-0065, Japan
  • Department of Neurosurgery, Tokyo Women's Medical University
    Shinjuku-ku, Tokyo-To 162-8666, Japan
  • Wakayama Medical University Hospital
    Wakayama, Wakayama 641-8510, Japan
  • Yamaguchi University Hospital
    Ube-shi, Yamaguchi 755-8505, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Sep 2024, 33 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 33 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2021
First posted
Oct 19, 2021
StartActual
Nov 18, 2021
Primary completionActual
Sep 11, 2024
CompletionActual
Sep 11, 2024
Results first posted
Oct 24, 2025
Last update
Oct 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05083923
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Oct 19, 2021
Start date
Nov 18, 2021
Primary completion
Sep 11, 2024
Completion
Sep 11, 2024
Results posted
Oct 24, 2025
Last update
Oct 24, 2025

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diroximel fumarate

Start the discussion